Salarius Pharmaceuticals, INC
Market Movers (8-K)
Decoy Therapeutics Inc. held its 2026 Annual Meeting of Stockholders, re-electing directors, approving executive compensation, and ratifying auditor appointment.
Decoy Therapeutics Inc. announced a private placement financing expected to yield approximately $3.5 million in gross proceeds to advance its lead asset into clinical trials.
Capital raise
Decoy Therapeutics Inc. announced its 2026 Annual Meeting of Stockholders will be held on July 14, 2026, with specific deadlines for shareholder proposals and director nominations.
Decoy Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement following a reverse stock split.
Capital raise
Decoy Therapeutics Inc. announced a 1-for-12 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.
Capital raise
Decoy Therapeutics Inc. stockholders approved a reverse stock split and a new equity incentive plan at a virtual special meeting held on February 24, 2026.
Quarterly Earnings (10-Q)
Decoy Therapeutics reports Q1 2026 financial results, highlighting ongoing development of its IMP3ACT platform and a focus on extending cash runway.
Capital raise
Salarius Pharmaceuticals completed its merger with Decoy Therapeutics, shifting focus to AI-driven peptide conjugates, and raised $6.3 million in a public offering, extending its cash runway to Q1 2027.
Capital raise
Salarius Pharmaceuticals reported a reduced net loss in Q2 2025, driven by cost-cutting, as it navigates a critical merger with Decoy Therapeutics and ongoing Nasdaq listing compliance challenges.
Delay expected
Worse than expected
Capital raise
Salarius Pharmaceuticals reports Q1 2025 results, highlighting ongoing losses, a proposed merger with Decoy Therapeutics, and challenges to maintain its Nasdaq listing.
Capital raise
Worse than expected
Salarius Pharmaceuticals reports a net loss of $972,121 for Q3 2024 and expresses substantial doubt about its ability to continue as a going concern due to insufficient funding.
Worse than expected
Delay expected
Capital raise
Salarius Pharmaceuticals is exploring strategic alternatives and implementing cost-saving measures due to financial constraints and has closed its Ewing sarcoma clinical trial, while a partial clinical hold impacts another trial.
Worse than expected
Delay expected
Capital raise
Annual Reports (10-K)
Decoy Therapeutics Inc. has filed an amendment to its 2025 Annual Report on Form 10-K, primarily to include previously omitted Part III information regarding directors, executive compensation, and corporate governance.
Delay expected
Decoy Therapeutics Inc. reports a significant net loss for 2025, addresses Nasdaq delisting concerns with a reverse stock split, and advances its AI-driven peptide conjugate pipeline following a strategic merger.
Worse than expected
Capital raise
Delay expected
Salarius Pharmaceuticals reports a net loss for 2024 and expresses substantial doubt about its ability to continue as a going concern, while pursuing a merger with Decoy Therapeutics to address its financial challenges.
Capital raise
Worse than expected
Salarius Pharmaceuticals has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive compensation, and corporate governance.
Delay expected
Salarius Pharmaceuticals reports a net loss of $12.5 million for 2023 and expresses substantial doubt about its ability to continue as a going concern without additional funding or a strategic transaction.
Worse than expected
Capital raise
Insider Trading (Form 4)
Salarius Pharmaceuticals Director Arnold C. Hanish sold a total of 27 common shares at $0.6397 per share on December 30, 2025, under a Rule 10b5-1 plan.
Salarius Pharmaceuticals Director Arnold C. Hanish acquired 5,000 shares of common stock at a weighted average price of $0.7481, increasing his indirect beneficial ownership.
Better than expected
Form 4: Salarius CFO Buys 20,000 Shares
Salarius Pharmaceuticals' Executive VP Finance and CFO, Mark J. Rosenblum, purchased 20,000 shares of common stock, signaling confidence in the company.
David J. Arthur, CEO of Salarius Pharmaceuticals, acquired 20,500 stock options on April 11, 2024.
Proxy Statements (Def-14A)
Decoy Therapeutics Inc. is holding a special meeting on September 14, 2026, to seek shareholder approval for the issuance of shares upon exercise of Milestone Warrants and to reduce authorized shares.
Capital raise
Decoy Therapeutics Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for July 14, 2026, to elect directors, vote on executive compensation, and ratify auditor appointment.
Decoy Therapeutics Inc. is calling a special meeting on February 24, 2026, to seek stockholder approval for a new equity incentive plan and a reverse stock split aimed at meeting Nasdaq's listing requirements following its merger.
Worse than expected
Capital raise
Delay expected
Salarius Pharmaceuticals, Inc. has supplemented its definitive proxy statement, announcing the adjournment of its 2025 Annual Meeting to December 31, 2025, and the engagement of Alliance Advisors for proxy solicitation.
Delay expected
Salarius Pharmaceuticals, Inc. has filed a Definitive Proxy Statement with the SEC, indicating its role as the registrant.
Salarius Pharmaceuticals, Inc. announced its 2025 Annual Meeting of Stockholders to be held virtually on December 19, 2025, to vote on director elections, executive compensation, and auditor ratification.
Worse than expected
New Public Companies (S-1)
Decoy Therapeutics Inc. has filed an S-1 registration statement to allow for the resale of up to 3,766,500 shares of common stock by selling stockholders, primarily from warrants issued in a recent private placement.
Worse than expected
Capital raise
Salarius Pharmaceuticals completes its merger with Decoy Therapeutics and initiates an $8 million public offering, significantly diluting existing shareholders while pivoting to a new peptide conjugate platform.
Delay expected
Worse than expected
Capital raise
Salarius Pharmaceuticals is merging with Decoy Therapeutics, shifting its focus to peptide conjugate drug discovery and raising $6.4M in a public offering.
Worse than expected
Capital raise
Delay expected
Salarius Pharmaceuticals and Decoy Therapeutics are progressing with their merger and a new financing round, while Salarius faces imminent Nasdaq delisting for non-compliance with listing rules.
Worse than expected
Delay expected
Capital raise
Salarius Pharmaceuticals, facing delisting from Nasdaq and significant financial challenges, is proceeding with a merger with preclinical-stage Decoy Therapeutics and a public offering aiming to raise $6.5 million to fund the combined entity's operations and pipeline.
Delay expected
Worse than expected
Capital raise
Salarius Pharmaceuticals is proceeding with a reverse merger with preclinical-stage Decoy Therapeutics, coupled with a public offering, as it faces significant Nasdaq delisting threats and aims to pivot its business focus to novel peptide conjugate therapeutics.
Delay expected
Worse than expected
Capital raise
Schedule 13G - Passive Investments
CVI Investments, Inc. and Heights Capital Management, Inc. have disclosed a 9.9% beneficial ownership stake in Decoy Therapeutics Inc., primarily through warrants.
CVI Investments, managed by Heights Capital Management, disclosed a 9.9% beneficial ownership stake in Salarius Pharmaceuticals, Inc., totaling 362,499 shares.
Intracoastal Capital LLC and its managers, Mitchell P. Kopin and Daniel B. Asher, reported a passive beneficial ownership of 4.99% in Salarius Pharmaceuticals, Inc. common stock.
Capital raise
C/M Capital Master Fund and related entities filed a Schedule 13G, reporting zero beneficial ownership in Salarius Pharmaceuticals, Inc. as of October 7, 2025.